A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment

NCT04332432 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Impairment

Interventions

DRUG: belapectin

Sponsor

Galectin Therapeutics Inc.